Natera is a diagnostics & research business based in the US. Natera shares (NTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Natera employs 2,958 staff and has a trailing 12-month revenue of around $931 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $45.82 |
|---|---|
| 52-week range | $34.00 - $63.00 |
| 50-day moving average | $51.98 |
| 200-day moving average | $49.03 |
| Wall St. target price | $73.87 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.47 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $45.82 from 2023-09-22
| 1 week (2023-09-15) | -11.03% |
|---|---|
| 1 month (2023-08-24) | -17.37% |
| 3 months (2023-06-23) | -10.80% |
| 6 months (2023-03-22) | -17.71% |
| 1 year (2022-09-20) | N/A |
|---|---|
| 2 years (2021-09-24) | -61.21% |
| 3 years (2020-09-24) | 64.88 |
| 5 years (2018-09-24) | 92.20% |
| Revenue TTM | $931 million |
|---|---|
| Gross profit TTM | $364 million |
| Return on assets TTM | -27.62% |
| Return on equity TTM | -98.35% |
| Profit margin | -54.97% |
| Book value | $5.23 |
| Market Capitalization | $6.1 billion |
TTM: trailing 12 months
We're not expecting Natera to pay a dividend over the next 12 months.
Over the last 12 months, Natera's shares have ranged in value from as little as $34.002 up to $63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Natera's is 1.1055. This would suggest that Natera's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Natera, Inc. , a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.